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Background: The clinical importance of tumor-infiltrating cluster of differentiation 4 (CD4) T cells is incompletely
understood in early breast cancer. We investigated the clinical significance of CD4, forkhead box P3 (FOXP3), and B
cell attracting chemokine leukocyte chemoattractant-ligand (C-X-C motif) 13 (CXCL13) in early breast cancer.
Methods: The study is based on the patient population of the randomized FinHer trial, where 1010 patients with
early breast cancer were randomly allocated to adjuvant chemotherapy containing either docetaxel or vinorelbine,
and human epidermal growth factor receptor 2 (HER2)-positive patients were also allocated to trastuzumab or no
trastuzumab. Breast cancer CD4, FOXP3, and CXCL13 contents were evaluated using quantitative real-time
polymerase chain reaction (qRT-PCR), and their influence on distant disease-free survival (DDFS) was examined
using univariable and multivariable Cox regression and Kaplan-Meier estimates in the entire cohort and in selected
molecular subgroups. Interactions between variables were analyzed using Cox regression. The triple-negative breast
cancer (TNBC) subset of the HE10/97 randomized trial was used for confirmation.
Results: High CXCL13 was associated with favorable DDFS in univariable analysis, and independently in multivariable
analysis (HR 0.44, 95% CI 0.29–0.67, P ≤ 0.001), most strongly in TNBC (HR 0.39, 95% CI 0.19–0.79, P = 0.009). No
significant interaction with chemotherapy or trastuzumab administration was detected. Neither tumor CD4 content nor
FOXP3 content was associated with DDFS. The favorable prognostic influence of CXCL13 was confirmed in the HE10/
97 trial patient population with TNBC (HR 0.30, 95% CI 0.09–0.93; P = 0.038).
Conclusions: The results provide a high level of evidence that humoral immunity influences the survival outcomes of
patients with early breast cancer, in particular of those with TNBC.
Trial registration: The study reports retrospective biomarker analyses in the prospective FinHer trial and the
prospective HE10/97 trial.
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Tumor-infiltrating lymphocytes (TILs) likely have an
important, albeit still incompletely understood, prog-
nostic and predictive role in breast cancer. For ex-
ample, a recent meta-analysis of 17 trials with 12,968
patients with breast cancer found that high numbers
of TILs were associated with favorable prognosis, and
that their numbers were predictive of achieving
pathological complete response (pCR) after neoadju-
vant chemotherapy [1]. Numerous studies have dealt
with the association of different subsets of T cells and
prognosis in breast cancer [2]. The importance of
cluster of differentiation 8 (CD8)-positive (CD8+)
cytotoxic T cells is well-established in breast cancer
[3], and CD4+ T cells have a central role in orches-
trating antitumoral immunity [4, 5].
The role of different subsets of lymphocytes and their
clinical significance in different molecular subgroups of
breast cancer is still unclear. To elucidate the prognostic
role of different subsets of CD4+ T cells in early breast
cancer, we focus here on the CD4+ cells, forkhead box
P3 (FOXP3) + CD4+ regulatory T cells (Tregs), and C-
X-C motif chemokine ligand 13 (CXCL13)-positive CD4
+ follicular helper T (Tfh) cells. FOXP3 drives the devel-
opment and function of Tregs that are engaged in the
maintenance of immunological self-tolerance and in
down-regulation of various immune responses [6].
CXCL13, formerly termed B cell-attracting chemokine 1,
is a cytokine that belongs to the CXC chemokine family,
which selectively attracts C-X-C motif receptor 5-
positive B cells (CXCR5) [7]. CXCL13-positive CD4+
Tfh cells are associated with a high frequency of peritu-
moral tertiary lymphoid structures and generally
favorable outcome in breast cancer [8]. Tfh cells express-
ing CXCL13 were recently found to convert Treg-
mediated immune suppression to activation of adaptive
antitumor humoral responses in breast cancer [9]. Tfh
cells and the CXLC13/CXCR5 axis are crucial for germi-
nal center development and antigen-specific B cell
maturation to high-affinity memory cells and antibody-
secreting plasma cells [10, 11].
We previously reported an association between a B
cell metagene, and, to a lesser extent, a T cell meta-
gene with favorable prognosis in patients with node-
negative breast cancer who did not receive adjuvant
therapy [12]. The strong favorable impact of the B
cell/plasma cell signature on prognosis was later con-
firmed by others [13]. In a recent comprehensive
meta-analysis of expression signatures from ∼ 8000
human tumors, Gentles and co-workers argued that
antigen-driven processes required for clonal expansion
and emergent humoral immune responses may be im-
portant for the prognostic significance of tumor-
infiltrating plasma cells [14]. In accordance with thishypothesis, we identified breast tumor-infiltrating plasma-
blasts and plasma cells using confocal microscopy as the
source of immunoglobulin kappa C (IGKC) expression,
and found them to be associated with favorable prognosis
[15]. However, the role of humoral/B cell-mediated
immunity in the development and clinical behavior of
breast cancer, or in outcome prediction, is not established,
although an increasing body of evidence suggests that
humoral immunity, too, is important.
We report here, to our knowledge for the first time,
based on a large study that the humoral immune function,
as approximated with cancer B cell-attracting chemokine
CXCL13 content, is associated with survival in early breast
cancer. The findings suggest that B cell-mediated immune
functions may be important for the clinical behavior of
breast cancer, particularly of the triple-negative subtype.Methods
Study population
In the FinHer trial (identifier ISRCTN76560285) 1010
patients with node-positive or high-risk node-negative
breast cancer were randomly assigned to either three cy-
cles of docetaxel or vinorelbine, followed by three cycles
of fluorouracil, epirubicin, and cyclophosphamide (FEC)
as adjuvant treatments [16]. Patients with human epider-
mal growth factor receptor 2 (HER2)-positive cancer by
chromogenic in situ hybridization (CISH) were further
randomized to nine weekly trastuzumab infusions, ad-
ministered concomitantly with chemotherapy, or to no
trastuzumab. Patients with hormone receptor-positive
cancer received tamoxifen. A review board at the
Helsinki University Hospital approved the study. Study
participants signed informed consent to allow research
assays to be carried out on their tumor tissue. This
retrospective biomarker study is reported according to
the Reporting Recommendations for Tumor Marker
Prognostic Studies (REMARK) criteria [17]. The charac-
teristics of the patients and the tumors are provided in
Table 1.
We used triple-negative breast cancer (TNBC) sam-
ples from the prospective HE10/97 trial (identifier
ACTRN12611000506998) to evaluate the prognostic
impact of CXCL13. The Hellenic Cooperative Oncology
Group (HeCOG) randomized a total of 595 high-risk
patients with breast cancer to postoperative dose-dense
sequential chemotherapy with epirubicin, followed by
cyclophosphamide, methotrexate, and fluorouracil (CMF)
with or without paclitaxel [18]. The clinical protocol and
the companion translational research studies were ap-
proved by local regulatory authorities and the Bioethics
Committee of the Aristotle University of Thessaloniki
School of Medicine, respectively. Written informed con-
sent was obtained from all patients. The characteristics of
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shown in Additional file 1: Table S1.
Breast cancer biological subtyping
In FinHer, cancer estrogen receptor (ER), progesterone re-
ceptor (PR), and human epidermal growth factor receptor-2
(HER2) expression were immunohistochemically assessed
according to the institutional guidelines. When HER2
expression was scored 2+ or 3+ (on a scale from 0 to 3+),
the number of copies of HER2 was centrally assessed with
CISH [16]. The tumors were considered hormone-receptor-
positive when ≥ 10% of cancer cells expressed ER and/or PR.
Immunohistochemical assessment for Ki-67 was done locally
using a Mib-1 monoclonal antibody (Dako, Glostrup,
Denmark). In the HE10/97 trial, tumor ER, PR, HER2, and
Ki-67 protein expression was assessed centrally as previously
described in detail [18]. Using these markers, breast cancers
were stratified as luminal A-like cancers (ER+ and/or PR+,
HER2−, Ki-67 ≤ 20%), luminal B-like cancers (ER+ and/or
PR+, HER2−, Ki-67 > 20%), HER2-positive cancers (ER and
PR positive or negative, HER2+), or triple-negative breast
cancers (TNBC; ER−, PR−, and HER2−).
CD4, FOXP, and CXCL13 assessments
Total RNA was extracted from 5-μm whole formalin-fixed
paraffin-embedded (FFPE) tissue sections with ≥ 30% of the
section surface area consisting of tumor. Tumor tissue was
available in 950 (94.1%) out of the 1010 cases. A sufficient
amount of RNA with good quality was isolated from 882
(87.3%) of the FFPE tumor specimens (Additional file 2:
Figure S1). CXCL 13, CD4, and FOXP3 was successfully
analyzed in 882 (87.3%), 876 (86.7%), and 874 (86.5%) tu-
mors, respectively.
In brief, RNA was first isolated using a fully automated
isolation method (XTRACT kit; STRATIFYER Molecular
Pathology GmbH, Cologne, Germany) using a liquid hand-
ling robot (XTRACT system; STRATIFYER Molecular
Pathology GmbH). Following deparaffinization, DNase I di-
gestion steps, and controls for the RNA quality, one-step
quantitative real-time (qRT)-PCR was done using a
custom-designed gene-specific Taq-Man-based assay to
measure cancer CXCL13, CD4, and FOXP3 content. Ex-
pression of CXCL13, CD4, FOXP3, and the reference gene
CALM2 mRNA were assessed in triplicates using the
SuperScript III Platinum One-Step Quantitative RT-PCR
System with ROX (Invitrogen, Karlsruhe, Germany) in a
Versant kPCR system (Siemens, Erlangen, Germany). The
thermal profile included 30 min at 50 °C, 20.5 min at 8 °C,
and 2 min at 95 °C followed by 40 cycles of 15 s at 95 °C,
and 30 s at 60 °C. The primer and probe sequences are
shown in Additional file 3: Table S2. The relative expression
levels of the genes of interest (GOI) were calculated as delta
cycle threshold (ΔCt) values (ΔCt = 40 − [CtGOI − Ct
(mean of CALM2)]. We stratified the samples using themedian breast tumor RNA expression as the cut-off value;
440 cancers had high and 442 had low CXCL13 expression
(median, 34.46), 437 had high and 438 had low FOXP3
expression (median, 31.01), and 438 had high and 439 had
low CD4 expression (median, 35.30).
To validate the prognostic impact of CXCL13 in an in-
dependent cohort, we analyzed TNBC tumor samples
from the HE10/97 trial cohort with 595 participants, of
whom 366 (62%) had samples available. Of these, 47
(13%) were TNBCs, and sufficient RNA was isolated
from 38 (81%) FFPE tumor specimens (Additional file 4:
Figure S2). When we stratified the samples using the
median breast tumor CXCL13 expression as the cutoff
value, 19 TNBCs had high and 19 had low CXCL13 ex-
pression (median, 34.21).Statistical analysis
The primary objective of this explorative study was to
evaluate the associations between CD4-positive T cells
and their subsets (CD4+/CXCL13+, CD4+/FOXP3+)
with distant disease-free survival (DDFS), which was the
survival endpoint in the final analysis of the FinHer trial
[16]. The secondary objectives were to study the influ-
ence of CD4, CXCL13, and FOXP3 expression in defined
molecular subtypes of breast cancer, and the associations
with the type of adjuvant therapy administered. DDFS
was defined as the time interval between the date of
randomization and the date of first cancer recurrence
outside of the ipsilateral local region or the date of
death, whenever death occurred before distant recur-
rence. Patients alive without documented evidence of
distant metastases were censored at the time of the
latest contact. DDFS rates were determined using
Kaplan-Meier estimates. Survival was compared between
groups using the log-rank test. The potential interactions
between tumor CXCL13 expression and the treatment
assigned were studied using a Cox proportional hazards
model containing the treatment group (docetaxel vs
vinorelbine, and trastuzumab vs no trastuzumab when the
tumor was HER2-positive), CXCL13 expression (high vs
low), and the treatment-by-biomarker interaction term.
Frequency tables were analyzed using Fisher’s exact test.
Association between tumor CXCL13, CD4, and
FOXP3 expression (tested ≤ median vs > median) and
DDFS was investigated using univariable and multivar-
iable Cox proportional hazards models. Other covari-
ables in the multivariable models were age at the time
of study entry (≤50 vs >50 years), breast tumor size
(pT1 vs pT2 vs pT3/T4), axillary nodal status (pN0 vs
pN1 vs pN2), histological grade of differentiation
(grade I vs II vs III), HER2 status (positive vs negative), ER
status (positive vs negative), PR status (positive vs nega-
tive), tumor Ki-67 expression (≤20% vs >20%), and cancer
Table 1 Associations between median cancer CXCL13 expression and patient and tumor characteristics
Characteristic PatientsNumber
(percentage)






pT1 368 (41.8) 172 (46.7%) 196 (44.7%)
pT2 437 (49.6) 226 (51.7%) 211 (48.3%)
pT3 76 (8.6) 45 (59.2%) 31 (40.8%) 0.099
Missing data 1
Axillary nodal status
pN0 93 (10.6) 45 (48.4%) 48 (51.6%)
pN1 761 (86.4) 384 (50.5%) 377 (495%)
pN2 27 (3.1) 14 (51.9%) 13 (48.1%) 0.922
Missing data 1
Histological grade
I 127 (15.0) 84 (66.1%) 43 (33.9%)
II 352 (41.6) 196 (55.7%) 156 (44.3%)
III 368 (43.4) 147 (39.9%) 221 (60.1%) < 0.001
Missing data 35
Age at study entry
<50 years 393 (44.6) 168 (42.7%) 225 (57.3%)
≥50 years 489 (55.4) 275 (56.2%) 214 (43.8%) < 0.001
Estrogen receptor status
Positive 635 (72.0) 360 (56.7%) 275 (43.3%)
Negative 247 (28.0) 83 (33.6%) 164 (66.4%) < 0.001
Progesterone receptor status
Positive 510 (57.9) 273 (53.5%) 237 (46.5%)
Negative 371 (42.1) 170 (45.8%) 201 (54.2%) 0.025
Missing data 1
HER2 status
Positive 199 (22.6) 80 (40.2%) 119 (59.8%)
Negative 683 (77.4) 363 (53.1%) 320 (46.9%) 0.002
Ki-67
≤20% (median) 396 (50.5) 219 (55.3%) 177 (44.7%)
>20% 388 (49.5) 161 (41.5%) 227 (58.5%) < 0.001
Missing data 98
Molecular subtype
Luminal A-like 331 (40.8) 190 (57.4%) 141 (42.6%)
Luminal B-like 148 (18.2) 77 (52.0%) 71 (48.0%)
Triple-negative 134 (16.5) 47 (35.1%) 87 (64.9%)
HER2-positive 199 24.5) 80 (40.2%) 119 (59.8%) < 0.001
Missing data 70
Assigned chemotherapy
Vinorelbine 437 (49.5) 210 (48.1%) 227 (51.9%)
Docetaxel 445 (50.5) 233 (52.4%) 212 (47.6%) 0.225
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Table 1 Associations between median cancer CXCL13 expression and patient and tumor characteristics (Continued)
Characteristic PatientsNumber
(percentage)





Trastuzumab given (if HER2+) cancers)
Yes 103 (52.2) 41 (39.8%) 62 (60.2%)
No 94 (47.7) 38 (40.4%) 56 (59.6%) 0.522
Abbreviations: CXCL13 C-X-C motif chemokine ligand 13, HER2 human epidermal growth factor receptor 2
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TNBC vs HER2-positive).
All P values are two-tailed, and P < 0.05 was consid-
ered significant. As all analyses are explorative and not
adjusted for multiple testing, the P values should be
interpreted with caution and in connection with the ef-
fect estimates. Statistical analyses were performed using
the Statistical Package for Social Science (SPSS) (SPSS
Inc., version 22, Chicago, IL, USA).
Results
Cancer biological subtypes
Of the 883 cancers, 331 (37.5%) were luminal A-like, 148
(16.8%) luminal B-like, 199 (22.5%) HER2-positive, 134
(15.2%) TNBC, and in 71 (8.0%) cases the subtype could
not be determined due to missing data on cancer Ki-67
expression.
Associations with patient and cancer characteristics
Cancer CD4, CXCL13, and FOXP3 expression correlated
positively with each other (P ≤ 0.001). Breast tumor expres-
sion of CXCL13 (Table 1) and of FOXP3 (Additional file 5:
Table S3) above the median value were both associated with
poor histological grade of differentiation, negative ER and
PR status, positive HER2 status, Ki-67 expression above the
median value, and with the HER2-positive and the TNBC
molecular subtypes, whereas CD4 (Additional file 6: Table
S4) expression was not associated with these variables.
Survival analyses
Cancer CXCL13 expression above the median value was
associated with favorable DDFS (HR 0.71, 95% CI 0.51–
0.99; P = 0.044), high FOXP3 content tended to be associ-
ated with unfavorable DDFS (HR 1.33, 95% CI 0.95–1.86;
P = 0.094), and tumor CD4 content was not associated
with DDFS (HR 0.99, 95% CI 0.71–1.39; P = 0.994; Fig. 1).
As expected, the standard prognostic factors were also as-
sociated with DDFS (Additional file 7: Table S5). When
the potential interactions between cancer CXCL13 con-
tent and systemic treatments with DDFS were examined,
there was no significant interaction with the type of
chemotherapy given or with administration versus no ad-
ministration of trastuzumab (Pinteraction = 0.255 and 0.325,
respectively).In a multivariable analysis high breast tumor median
CXCL13 content was independently associated with fa-
vorable DDFS (HR 0.44, 95% CI 0.29–0.67; P ≤ 0.001),
whereas CD4 content and FOXP3 content were not (HR
1.89, 95% CI 0.80–1.78; P = 0.396; and HR 1.20, 95% CI
0.78–1.84; P = 0.400, respectively). Besides CXCL13,
only the axillary nodal status and the molecular subtypes
had independent prognostic value (Table 2).Influence on survival in molecular subsets
The influence of cancer CXCL13 content on DDFS was
most evident in the TNBC subset (Table 3). In univari-
able survival analyses, high tumor CXCL13 content was
significantly associated with favorable DDFS in TNBC
(HR 0.42, 95% CI 0.22–0.83, P = 0.012) unlike the other
molecular subtypes (Fig. 2). Tumor CXCL13 content also
had an independent influence on DDFS in a multivari-
able analysis adjusted for age at the time of study entry,
tumor size, axillary nodal status, and histological grade
of differentiation (HR 0.39, 95% CI 0.19–0.79; P = 0.009;
Table 3).
Unlike CXCL13, FOXP3 (Additional file 8: Table S6)
and CD4 (Additional file 9: Table S7) content in tumor
tissue was not significantly associated with DDFS in any
of the four molecular subtypes, respectively.
The association between high median tumor CXCL13
content and favorable DDFS in TNBC was confirmed in
the HE10/97 trial population (HR 0.30, 95% CI 0.09–
0.93; P = 0.038) (Fig. 3).Discussion
High tumor CXCL13 expression was associated with
several factors that are generally associated with poor
survival in breast cancer, such as low cancer histo-
logical grade of differentiation, high Ki-67 expression,
and negative ER expression in the FinHer trial patient
population. Despite this, high cancer CXCL13 expres-
sion was associated with favorable DDFS in univari-
able survival analysis, and tumor CXCL13 expression
had an independent influence on survival also in a
multivariable model. The prognostic influence was
most marked in the subset of patients with TNBC,
which we confirmed in an independent series of
ac
b
Fig. 1 Influence of the median breast cancer CXCL13 content (a), forkhead box P3 (FOXP3) content (b), and CD4 content (c) on distant disease-
free survival in the FinHER trial
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HE10/97 trial.
CXCL13+/CD4+ Tfh cells are crucial for germinal
center development, and their presence is associated
with extensive lymphocyte infiltration and formation of
peritumoral tertiary lymphoid follicles [8]. In a study on
early breast cancer in which the patients had not re-
ceived systemic treatment, presence of CXCL13 Tfh cells
in cancer predicted longer survival and a high pCR rate
after preoperative chemotherapy [8]. Similarly, in the
neoadjuvant GeparSixto trial a high cancer CXCL13
mRNA content was associated with a high pCR rate
[19]. We and others have found that in retrospective
studies high expression of B cell-related transcripts is as-
sociated with favorable survival in early breast cancer[12–15, 20–22]. To our knowledge this study is the first
one showing that in a large randomized trial patient
population high B cell-attracting chemokine CXCL13 is
independently associated with favorable survival out-
comes, indicating an important role of the humoral im-
mune response in disease control among patients with
early breast cancer.
We [23] and others [8] have reported significant asso-
ciation between high tumor CXCL13 content and favor-
able survival among patients with HER2-positive cancer
not treated with trastuzumab. We did not confirm this
finding in the present study in which half of the patients
were treated with trastuzumab. The host immune
system likely contributes to trastuzumab efficacy [24].
Loi and co-workers did not identify a significant
Table 2 Multivariable Cox regression analysis for distant
disease-free survival
Covariable Distant disease-free survivalHR (95% CI) P
CXCL13 expression
≤ Median ref.
> Median 0.44 (0.29–0.67) < 0.001
FOXP3 expression
≤ Median ref. 0.400
> Median 1.20 (0.78–1.84)
CD4 expression
≤ Median ref. 0.396
> Median 1.89 (0.80–1.78)
Age at study entry
≤50 years Ref. 0.516
>50 years 0.88 (0.62–1.27)
Tumor size 0.105
pT1 Ref.
pT2 1.22 (0.82–1.81) 0.330
pT3 1.89 (1.05–3.40) 0.034
Axillary nodal status < 0.001
pN0 Ref.
pN1 4.51 (1.94–10.52) < 0.001
pN2 14.27 (4.78–42.71) < 0.001
Histological grade 0.229
I Ref.
II 2.06 (0.86–4.95) 0.105
III 2.22 (0.88–5.52) 0.088
Molecular subtype < 0.001
Luminal A-like Ref.
Luminal B-like 1.79 (1.01–3.14) 0.045
Triple-negative 4.18 (2.30–7.59) < 0.001
HER2-positive 2.71 (1.56–4.68) < 0.001
Abbreviations: CD4 cluster of differentiation 4, CI confidence interval, CXCL13
C-X-C motif chemokine ligand 13, FOXP3 forkhead box P3, HER2 human
epidermal growth factor receptor 2, HR hazard ratio
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among patients with HER2-positive cancer in the FinHer
patient population, but detected an interaction between a
high tumor TIL content and trastuzumab benefit [25].
The association between TILs and the benefit fromTable 3 Association between breast cancer median CXCL13 conten
Subtype Univariable modelHR (95% CI)
Luminal A-like 0.60 (0.27–1.34)
Luminal B-like 0.59 (0.27–1.28)
Triple-negative 0.42 (0.22–0.83)
HER2-positive 0.78 (0.43–1.42)
Abbreviations: CI confidence interval, HR hazard ratio, HER2 human epidermal growttrastuzumab is controversial, as conflicting results were
obtained from the N9831 trial [26]. In the present analysis,
we did not find a significant interaction between cancer
CXCL13 expression and trastuzumab treatment. Potential
explanations for these seemingly conflicting results in
HER2-positive disease include differences in the study
methodology (TILs were assessed either immunohisto-
chemically or by gene expression analyses), the compo-
nents of the immune system addressed differed (CXCL13
assays reflect mainly the humoral immunity only), and dif-
ferences in the trial designs that may have influenced the
immune function (in FinHer trastuzumab was adminis-
tered up front, in N9831 doxorubicin plus cyclophospha-
mide were administered prior to starting trastuzumab).
The current results in TNBC are well in an agreement
with previous findings. A high tumor TIL content has
been found to be associated with favorable survival in
TNBC [25, 27, 28]. Using DNA microarray gene expres-
sion analysis we demonstrated that three “coordinates in
breast cancer” - proliferation, ER, and the immune
system - facilitate orientation and help to correctly inter-
pret breast cancer biology. Based on the extent of
immune-related transcripts we defined two subtypes of
basal-like breast cancer, namely basal-like A (advanta-
geous prognosis) and basal-like B (bad prognosis) [29].
Later, this notion of the importance of immune infil-
trates especially in triple-negative breast cancer was
convincingly refined and elaborated by Lehmann and
co-workers [30, 31]. The association between high
cancer TIL content and survival in TNBC may not be
surprising, since the overall mutation rate is the highest
in the basal-like and HER2-enriched subtypes [32]. A
high mutation load leads to an increased presentation of
neo-antigens to immune cells resulting in pronounced
lymphocytic infiltrates, which may be a biomarker for
cancer immunotherapy [33]. A recent retrospective ana-
lysis, however, challenged this association and reported
that lymphocyte-rich TNBC had significantly lower mu-
tation and neo-antigen counts than lymphocyte-poor
TNBC [34]. Nonetheless, most of the immunogenic
mutanome is recognized by the CD4+ T cells, and
vaccination with CD4+ immunogenic mutations leads to
strong antitumor activity [35, 36]. These findings may
have important potential implications for breast cancer
immunotherapy. The first results with immune checkpointt and distant disease-fee survival in four molecular subtypes
P Multivariable modelHR (95% CI) P
0.214 0.57 (0.24–1.34) 0.194
0.180 0.49 (0.20–1.17) 0.109
0.012 0.39 (0.19–0.79) 0.009
0.421 0.75 (0.40–1.41) 0.372
h factor receptor 2
a b
c d
Fig. 2 Influence of the median breast cancer CXCL13 content on distant disease-free survival in luminal A-like cancer (a), luminal B-like cancer (b),
human epidermal growth factor receptor 2 (HER2)-positive cancer (c), and triple-negative cancer (d) in the FinHER trial
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grammed cell death protein 1 (PD-1), seem encouraging
with clinical responses in some heavily pretreated patients
with advanced TNBC [37]. Evaluation of the B cell response
biomarker CXCL13 in addition to PD-L1 testing might be
useful to further enrich such responsive patients.
Unlike CXCL13, the median tumor CD4 or FOXP3
contents were not significantly associated with DDFS.
Since CD4 is expressed in many T cell subsets including
T helper 1 (Th1) cells, T helper 2 (Th2) cells, T helper
17 (Th17) cells, Tfh cells, and Tregs, each of which may
have a different impact on prognosis, this observation
may be expected. Prior studies based on immunohisto-
chemical assessment that have addressed the prognosticsignificance of FOXP3+ Tregs have shown conflicting
results [38–41].
The potential weakness of the study is that it was ex-
ploratory, and that we may have lacked the statistical power
to detect small effects on survival, in particular in the mo-
lecular subgroups. The systemic therapy consisted of sev-
eral agents, which is a potential confounding factor, as the
agents might have varying effects on the immune system.
The strength of the study is that we report the prognostic
significance of CD4+ T cell subsets in a large randomized
trial, and confirmed the prognostic impact of CXCL13 in
TNBC in an independent cohort. This allows a high level
of evidence when evaluating prognostic or predictive bio-
markers [42].
Fig. 3 Influence of the median breast cancer CXCL13 content on
distant disease-free survival in triple-negative cancer in the
HE1097 trial
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The present results suggest that the humoral immune
function has prognostic significance in early breast cancer.
The prognostic effect of cancer CXCL13 content was
most pronounced in the subset of patients with TNBC. In
general, the current results provide a high level of evi-
dence for the independent prognostic role of CXCL13 and
lend support for immunotherapeutic interventions that
may strengthen the immune response, especially in pa-
tients with TNBC.
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